Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genome-guided targeted therapy versus standard maintenance in metastatic non-small cell lung cancer
2013-001653-27Phase 2Completed
- Sponsor
- Unicancer
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vistusertib, fexagratinib, capivasertib, sapitinib, selumetinib and 1 more in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Unicancer. Primary endpoint: Progression-free survival. Started Sep 2015; status: completed.
02
Drugs
vistusertibfexagratinibcapivasertibsapitinibselumetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2013-001653-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001653-27.